 |
【ケースレポート】に関する参考文献
■Case Report Ｎｏ．をクリックしてください。
【ケースレポート】に関する参考文献
|
Case Report No. |
No. |
Title |
Author |
Journal |
Vol&Page |
Year |
Pub Med ID |
2 |
|
Cancer Mortality and Morbidity statistics. |
Tominaga S, Oshima A et al. |
Japanese Cancer Association. |
174-175 |
1999 |
|
2 |
膵臓全国登録調査報告（20年間の統括） |
膵臓登録委員会 |
膵臓 |
18:97-169 |
2003 |
|
3 |
Adoptive immunotherapy for unresectable or recurrent pancreatic cancer, using lymphokine-activated killer cells or cytotoxic T cells |
Oka Masaaki, Suzuki Kichinari, et al |
Journal of Hepato-Biliary Pancreatic Surgery |
2:163-167 |
1994 |
|
4 |
Adoptive immunotherapy for pancreatic cancer, using MUC1 specific CTL. |
Masaki Y, Oka M |
Gan To Kagaku Ryoho. |
23(12):1679-80. |
1996 |
|
5 |
Efficacy of immuno-cell therapy in patients with advanced pancreatic cancer. |
Kaneko T, Goto S, Kato A, Akeyama A, Tomonaga M, Fujimoto K, Miyamoto Y, Eriguchi M, Egawa K. |
Anticancer Res. |
25(6A):3709-14. |
2005 |
|
6 |
Effect of intraportal adoptive immunotherapy on liver metastases after resection of pancreatic cancer. |
Kobari M, Egawa S, Shibuya K, Sunamura M, Saitoh K, Matsuno S. |
Br J Surg. |
87(1):43-8. |
2000 |
|
7 |
膵癌に対する養子免疫療法 |
鈴木道成、岡 正朗、他 |
胆と膵 |
16:509-516 |
1995 |
|
3 |
|
Lymphokine-activated killer (LAK) and monocyte-mediated cytotoxicity on tumor cell lines resistant to antitumor agents. |
Allavena P, Damia G, Colombo T, Maggioni D, D'Incalci M, Mantovani A.
|
Cell Immunol. |
120(1):250-8. |
1989 |
|
2 |
Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. |
Fujita K, Ikarashi H, Takakuwa K, Kodama S, Tokunaga A, Takahashi T, Tanaka K.
|
Clin Cancer Res. |
1(5):501-7. |
1995 |
|
3 |
Restoration of tumor specific human leukocyte antigens class I-restricted cytotoxicity by dendritic cell stimulation of tumor infiltrating lymphocytes in patients with advanced ovarian cancer. |
Santin AD, Bellone S, Palmieri M, Bossini B, Cane' S, Bignotti E, Roman JJ, Cannon MJ, Pecorelli S. |
Int J Gynecol Cancer. |
14(1):64-75. |
2004 |
|
4 |
Use of adoptive transfer of tumor-infiltrating lymphocytes alone or in combination with cisplatin-containing chemotherapy in patients with epithelial ovarian cancer. |
Aoki Y, Takakuwa K, Kodama S, Tanaka K, Takahashi M, Tokunaga A, Takahashi T. |
Cancer Res. |
51(7):1934-9. |
1991 |
|
5 |
Postoperative adjuvant immunochemotherapy using Lentinan for advanced gastric carcinoma patients with metastasis in the regional lymph nodes and serosal invasion |
Kagawa R, Nakayama N, Yamaguchi T, Sakata S, Tada M. |
Gan To Kagaku Ryoho. |
29(11):1989-94. |
2002 |
|
6 |
Successful treatment of a patient with recurrent ovarian cancer by lentinan combined with intraarterial 5FU |
Shimizu Y, Hasumi K, Chen JT, Hirai Y, Nakayama K, Teshima H, Hamada T, Fujimoto I, Yamauchi K, Masubuchi K. |
Nippon Gan Chiryo Gakkai Shi. |
24(3):647-51. |
1989 |
|
4 |
|
第１６回全国原発性肝癌追跡調査報告 |
|
|
|
2000-2001 |
|
2 |
Recurrence of hepatocellular carcinoma after surgery.
|
Yamamoto J, Kosuge T, Takayama T, Shimada K, Yamasaki S, Ozaki H, Yamaguchi N, Makuuchi M. |
Br J Surg. |
83(9):1219-22. |
1996 |
|
3 |
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. |
Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. |
Lancet. |
356(9232):802-7. |
2000 |
|
4 |
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. |
Hanson HL, Donermeyer DL, Ikeda H, White JM, Shankaran V, Old LJ, Shiku H, Schreiber RD, Allen PM. |
Immunity. |
13(2):265-76. |
2000 |
|
5 |
Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. |
Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. |
Adv Immunol. |
74:181-273. |
2000 |
|
6 |
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. |
Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. |
Science. |
298(5594):850-4. Epub 2002 Sep 19. |
2002 |
|
7 |
|
Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. |
Dillman RO, Herndon J, Seagren SL, Eaton WL Jr, Green MR. |
J Natl Cancer Inst. |
88(17):1210-5. |
1996 |
|
2 |
A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. |
Kimura H, Yamaguchi Y. |
Cancer. |
80(1):42-9. |
1997 |
|
3 |
A randomized phase III trial of adjuvant chemotherapy with UFT for completely resected pathological stage I non-small-cell lung cancer: the West Japan Study Group for Lung Cancer Surgery (WJSG)--the 4th study. |
Nakagawa M, Tanaka F, Tsubota N, Ohta M, Takao M, Wada H; West Japan Study Group for Lung Cancer Surgery. |
Ann Oncol. |
16(1):75-80. |
2005 |
|
8 |
|
がん診療レジデントマニュアル第３版 |
国立がんセンター中央病院内科レジデント |
|
|
|
|
2 |
Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. |
Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH Jr, Benz LA, Fefer A.
|
J Clin Oncol. |
10(6):960-8 |
1992 |
|
3 |
Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results. |
Tomita Y, Katagiri A, Saito K, Imai T, Saito T, Tanikawa T, Terunuma M, Nishiyama T, Takahashi K.
|
Int J Urol. |
5(1):16-21. |
1998 |
|
4 |
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d'Immunotherapie. |
Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T.
|
N Engl J Med. |
338(18):1272-8. |
1998 |
|
5 |
Immunotherapy of metastatic kidney cancer. |
Pizza G, De Vinci C, Lo Conte G, Maver P, Dragoni E, Aiello E, Fornarola V, Bergami T, Busutti L, Boriani S, Palareti A, Capanna R. |
Int J Cancer. |
94(1):109-20. |
2001 |
|
9 |
|
がん診療レジデントマニュアル第3版：国立がんセンター中央病院内科レジデント編 |
|
|
|
|
|
2 |
A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. |
Kimura H, Yamaguchi Y. |
Cancer. |
80(1):42-9. |
1997 |
|
3 |
Cytokines in lung cancer. |
Chyczewska E, Mroz RM |
Rocz Akad Med Bialymst. |
42 Suppl 1:8-22. |
1997 |
|
4 |
Non-surgical therapy for patients with advanced non-small cell lung cancer. |
Liao M. |
Respirology. |
3(3):151-7. |
1998 |
|
10 |
|
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. |
Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, et al. |
N Engl J Med. |
316(15):889-97. |
1987 |
|
2 |
転移性肺腫瘍に対する胸腔鏡手術 |
中島 淳、高本眞一 |
外科治療 |
88 ： 1094 |
2003 |
|
11 |
|
Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. |
Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K, Horikoshi N, Okamura T, Hirata K, Saitoh S, Isomoto H, Satoh A. |
Cancer. |
100(11):2355-61. |
2004 |
|
12 |
|
がん診療レジデントマニュアル第3版：国立がんセンター中央病院内科レジデント編 |
|
|
|
|
|
2 |
Low-dose paclitaxel therapy as second-line chemotherapy for patients who previously received TS-1 therapy |
Takemura M, Osugi H, Lee S, Kaneko M, Tanaka Y, Fujiwara Y, Nishizawa S, Iwasaki H. |
Gan To Kagaku Ryoho. |
31(13):2183-6. |
2004 |
|
3 |
Weekly paclitaxel therapy is useful for gastric carcinoma as second-line chemotherapy |
Mizuiri H, Yoshida K, Shimizu K, Tanabe K, Taomoto J, Suzuki T, Wada Y, Hihara J. |
Gan To Kagaku Ryoho. |
31(12):2043-6. |
2004 |
|
4 |
A case responding to weekly paclitaxel therapy as second-line chemotherapy for gastric cancer previously treated with TS-1 |
Imamura H, Furukawa H, Kishi K, Tatsuta M, Masutani S, Fukunaga M, Nakayama T, Shimizu J, Takemoto H, Kishimoto T, Kato H, Yamamoto K, Fujishima M, Kawasaki T. |
Gan To Kagaku Ryoho. |
31(11):1693-5 |
2004 |
|
5 |
Weekly administration of paclitaxel as a second-line chemotherapy for advanced and recurrent gastric cancer |
Makari Y, Fujiwara Y, Yasuda T, Takiguchi S, Kimura Y, Yano M, Monden M. |
Gan To Kagaku Ryoho. |
31(4):609-11. |
2004 |
|
15 |
|
Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. |
Fujita K, Ikarashi H, Takakuwa K, Kodama S, Tokunaga A, Takahashi T, Tanaka K. |
Clin Cancer Res. |
1(5):501-7. |
1995 |
|
2 |
A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. |
Kimura H, Yamaguchi Y. |
Cancer. |
80(1):42-9. |
1997 |
|
3 |
Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. |
Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. |
Lancet. |
356(9232):802-7. |
2000 |
|
16 |
|
Stimulation of gammadelta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. |
Kunzmann V, Bauer E, Feurle J, Weissinger F, Tony HP, Wilhelm M. |
Blood. |
96(2):384-92. |
2000 |
|
2 |
Gammadelta T cells for immune therapy of patients with lymphoid malignancies. |
Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP. |
Blood. |
102(1):200-6 |
2003 |
|
参考資料 |
Requirement of species-specific interactions for the activation of human gamma delta T cells by pamidronate. |
Kato Y, Tanaka Y, Tanaka H, Yamashita S, Minato N. |
J Immunol. |
170(7):3608-13 |
2003 |
|
17 |
|
がん診療レジデントマニュアル第3版：国立がんセンター中央病院内科レジデント編 |
|
|
|
|
|
2 |
C型肝硬変症例における肝細胞癌の発生に対するインターフェロン治療の効果 |
柿原幸司，持田智，大西久仁彦，藤原研司. |
埼玉医科大学雑誌第29巻第4号 |
205-211 |
2002 Oct |
|
3 |
Life-prolonging effect of immunocell BAK (BRM-activated killer) therapy for advanced solid cancer patients: prognostic significance of serum immunosuppressive acidic protein levels. |
Ebina T, Ogama N, Shimanuki H, Kubota T, Isono N. |
Cancer Immunol Immunother. |
52(9):555-60. |
2003 |
|
4 |
Long-term prognosis of hepatocellular carcinoma patients treated with adoptive immunotherapy |
Takeda T, Watanabe M, Umeshita K, Goto M, Monden M. |
Gan To Kagaku Ryoho. |
31(11):1646-8. |
2004 |
|
18 |
|
Immuno-cell therapy of cancer in Japan. |
Egawa K. |
Anticancer Res. |
24(5C):3321-6. |
2004 |
|
2 |
Enhanced apoptosis of squamous cell carcinoma cells by interleukin-2-activated cytotoxic lymphocytes combined with radiation and anticancer drugs. |
Yamamoto T, Yoneda K, Ueta E, Doi S, Osaki T. |
Eur J Cancer. |
36(15):2007-17. |
2000 |
|
3 |
The combined effect of lymphokine activated killer cell and radiation therapy on rat brain tumor in vitro. |
Nakagawa K, Omori N, Hashimoto K, Yamamoto T, Tsunoda T, Nose T. |
Biotherapy. |
4(2):109-15. |
1992 |
|
4 |
Synergy of radiation therapy and immunotherapy in murine renal cell carcinoma. |
Dybal EJ, Haas GP, Maughan RL, Sud S, Pontes JE, Hillman GG. |
J Urol. |
148(4):1331-7. |
1992 |
|
5 |
Personal communication |
Kamahora T. |
|
|
|
|
6 |
Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors. |
Awwad M, North RJ. |
Cancer Res. |
50(8):2228-33. |
1990 |
|
19 |
|
Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial. |
Kono K, Takahashi A, Ichihara F, Amemiya H, Iizuka H, Fujii H, Sekikawa T, Matsumoto Y. |
Clin Cancer Res. |
8(6):1767-71. |
1990 |
|
20 |
|
Histological typing of lung and pleural tumours, 3rd ed. World Health Organization International Histological Classification of Tumours. |
Travis WD, Colby TV, Corrin B, Shimosato Y, Brambilla E. |
Berlin |
Springer |
1999 |
|
2 |
Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. |
Gridelli C, Perrone F, Gallo C, Cigolari S, Rossi A, Piantedosi F, Barbera S, Ferrau F, Piazza E, Rosetti F, Clerici M, Bertetto O, Robbiati SF, Frontini L, Sacco C, Castiglione F, Favaretto A, Novello S, Migliorino MR, Gasparini G, Galetta D, Iaffaioli RV, Gebbia V; MILES Investigators. |
J Natl Cancer Inst. |
95(5):362-72. |
2003 |
|
22 |
|
Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. |
Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, Camphausen K, Luiten RM, de Ru AH, Neijssen J, Griekspoor A, Mesman E, Verreck FA, Spits H, Schlom J, van Veelen P, Neefjes JJ. |
J Exp Med. |
203(5):1259-71 |
2006 |
|
2 |
切除不能膵癌にgemcitabine・少線量放射線・CD3‐LAKによる集学的治療が有効であった1例 |
加藤昭, 明山耀久, 河合公三 |
Biotherapy. |
20(1):87-90 |
2006 |
|
|
|
|
|
|
|
|
|
|
